Apollomics Inc. Overview
Pro stress-test →Apollomics is a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment landscape for patients with few or no options. The company's pipeline focuses on targeted therapies for difficult-to-treat cancers, with a lead program in vebreltinib for MET-altered non-small cell lung cancer and other solid tumors.
Strategic Profile
Pro stress-test →The company's primary focus is to advance global development of vebreltinib for treatment of patients with c-MET alterations, with plans to submit an IND Application for accelerated approval in NSCLC in the first half of 2027. Beyond its lead c-Met inhibitor, the pipeline includes uproleselan for acute myeloid leukemia and three new immuno-oncology candidates (APL-501, APL-502, APL-801) with mono-specific and bi-specific antibodies.
Competitive Landscape
Pro stress-test →Apollomics competes with other early-stage oncology biotech firms in targeted therapies for lung cancer and hematologic malignancies. Key competitors include Mersana Therapeutics, AnaptysBio, and Altimmune, though most peers are similarly capitalized. The company's c-Met and immuno-oncology focus positions it in crowded but high-value oncology segments where larger pharma and well-capitalized biotechs (e.g., Eli Lilly, Novartis, Roche) also compete.
Industry Context
Apollomics Inc. operates in Oncology therapeutics.
Key facts
Founded: 2015 · Headquarters: Foster City, US · Revenue: $8.5M · Market cap: $32.2M